GlassScriptPhysician profile
Melissa Felder
NPI 1104320738
$3,076.16
in general payments reported to CMS, 2019-2025
24 companies · $592 in 2025
The $592 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $830 · 2022: $330 · 2023: $755 · 2024: $569 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,916.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.17 | 2021-2024 | |
| Novo Nordisk INC | $271.94 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $252.44 | 2021-2025 | Airsupra |
| Gilead Sciences, INC. | $205.68 | 2023-2025 | Epclusa |
| Alkermes, INC. | $190.42 | 2021-2025 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $139.44 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $130.95 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $129.31 | 2022 | |
| Idorsia Pharmaceuticals US INC | $124.86 | 2024 | Quviviq |
| Genzyme Corporation | $124.80 | 2024 | |
| Viiv Healthcare Company | $118.23 | 2025 | |
| Janssen Pharmaceuticals, INC | $116.70 | 2023 | Invega Sustenna, Invega Trinza |
| Novartis Pharmaceuticals Corporation | $110.16 | 2023-2024 | |
| Insmed, INC. | $104.18 | 2021 | |
| Abbott Laboratories | $92.75 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $86.95 | 2023 | |
| Argenx US, INC. | $85.99 | 2022 | |
| Boston Scientific Corporation | $80.32 | 2021 | |
| Genentech USA, INC. | $61.97 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $51.84 | 2021 | |
| Sanofi Pasteur INC. | $32.93 | 2023 | |
| Insulet Corporation | $24.88 | 2024 | Omnipod |
| Phathom Pharmaceuticals, INC. | $16.75 | 2025 | Voquezna |
| Lilly USA, LLC | $14.50 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Felder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.